David Risinger
Stock Analyst at Leerink Partners
(3.76)
# 846
Out of 4,413 analysts
97
Total ratings
67.09%
Success rate
17.17%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Initiates: Outperform | $47 | $24.34 | +93.10% | 1 | Apr 16, 2024 | |
| AMGN Amgen | Upgrades: Outperform | $267 → $318 | $273.94 | +16.08% | 4 | Oct 11, 2023 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $6 → $11 | $9.16 | +20.09% | 2 | Aug 15, 2023 | |
| BMY Bristol-Myers Squibb Company | Initiates: Market Perform | $66 | $43.94 | +50.20% | 3 | Jul 10, 2023 | |
| LLY Eli Lilly | Maintains: Outperform | $410 → $458 | $781.10 | -41.36% | 13 | May 1, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $834 → $976 | $890.66 | +9.58% | 6 | Mar 27, 2023 | |
| HALO Halozyme Therapeutics | Downgrades: Market Perform | $42 | $38.10 | +10.24% | 3 | Mar 16, 2023 | |
| ABBV AbbVie | Upgrades: Market Perform | $135 → $153 | $162.64 | -5.93% | 4 | Feb 10, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $374 → $365 | $392.81 | -7.08% | 3 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Market Perform | $81 → $91 | $65.20 | +39.57% | 3 | Feb 3, 2023 | |
| PFE Pfizer | Maintains: Market Perform | $49 → $48 | $25.62 | +87.35% | 9 | Feb 1, 2023 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $194 → $186 | $144.59 | +28.64% | 2 | Jan 20, 2023 | |
| ROIV Roivant Sciences | Maintains: Outperform | $8 → $10 | $10.90 | -8.26% | 4 | Dec 19, 2022 | |
| PCVX Vaxcyte | Initiates: Outperform | $60 | $60.55 | -0.91% | 1 | Dec 16, 2022 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $12 → $14 | $8.44 | +65.88% | 2 | Nov 17, 2022 | |
| RDUS Radius Health | Maintains: Market Perform | $7 → $10 | $17.42 | -42.59% | 2 | Jun 24, 2022 | |
| HLVX HilleVax | Initiates: Outperform | $30 | $13.20 | +127.27% | 1 | May 24, 2022 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $35 → $37 | $18.61 | +98.82% | 2 | Feb 22, 2022 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Equal-Weight | n/a | $110.75 | - | 3 | Apr 1, 2021 | |
| VTRS Viatris | Maintains: Equal-Weight | n/a | $11.57 | - | 1 | Mar 10, 2021 | |
| PRGO Perrigo Company | Maintains: Equal-Weight | n/a | $32.66 | - | 5 | Mar 5, 2021 | |
| BHC Bausch Health Companies | Maintains: Equal-Weight | n/a | $8.76 | - | 1 | Feb 26, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | n/a | $13.16 | - | 2 | Aug 20, 2020 | |
| RPRX Royalty Pharma | Initiates: Equal-Weight | n/a | $27.70 | - | 1 | Jul 13, 2020 | |
| ZTS Zoetis | Maintains: Equal-Weight | n/a | $159.24 | - | 2 | Apr 2, 2020 | |
| TEVA Teva Pharmaceutical | Maintains: Underweight | n/a | $14.05 | - | 9 | Apr 2, 2020 | |
| MRK Merck & Co. | Maintains: Overweight | n/a | $129.22 | - | 6 | Apr 2, 2020 | |
| ALKS Alkermes | Maintains: Equal-Weight | n/a | $24.54 | - | 1 | Apr 2, 2020 | |
| AMRX Amneal Pharmaceuticals | Downgrades: Equal-Weight | n/a | $6.05 | - | 1 | Dec 14, 2018 |
AnaptysBio
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $24.34
Upside: +93.10%
Amgen
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $273.94
Upside: +16.08%
Centessa Pharmaceuticals
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $9.16
Upside: +20.09%
Bristol-Myers Squibb Company
Jul 10, 2023
Initiates: Market Perform
Price Target: $66
Current: $43.94
Upside: +50.20%
Eli Lilly
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $781.10
Upside: -41.36%
Regeneron Pharmaceuticals
Mar 27, 2023
Upgrades: Outperform
Price Target: $834 → $976
Current: $890.66
Upside: +9.58%
Halozyme Therapeutics
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $38.10
Upside: +10.24%
AbbVie
Feb 10, 2023
Upgrades: Market Perform
Price Target: $135 → $153
Current: $162.64
Upside: -5.93%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $392.81
Upside: -7.08%
Gilead Sciences
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $65.20
Upside: +39.57%
Pfizer
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.62
Upside: +87.35%
Johnson & Johnson
Jan 20, 2023
Maintains: Outperform
Price Target: $194 → $186
Current: $144.59
Upside: +28.64%
Roivant Sciences
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $10.90
Upside: -8.26%
Vaxcyte
Dec 16, 2022
Initiates: Outperform
Price Target: $60
Current: $60.55
Upside: -0.91%
Theravance Biopharma
Nov 17, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $8.44
Upside: +65.88%
Radius Health
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $17.42
Upside: -42.59%
HilleVax
May 24, 2022
Initiates: Outperform
Price Target: $30
Current: $13.20
Upside: +127.27%
Organon & Co.
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $18.61
Upside: +98.82%
Jazz Pharmaceuticals
Apr 1, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $110.75
Upside: -
Viatris
Mar 10, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $11.57
Upside: -
Perrigo Company
Mar 5, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $32.66
Upside: -
Bausch Health Companies
Feb 26, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $8.76
Upside: -
Elanco Animal Health
Aug 20, 2020
Upgrades: Overweight
Price Target: n/a
Current: $13.16
Upside: -
Royalty Pharma
Jul 13, 2020
Initiates: Equal-Weight
Price Target: n/a
Current: $27.70
Upside: -
Zoetis
Apr 2, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $159.24
Upside: -
Teva Pharmaceutical
Apr 2, 2020
Maintains: Underweight
Price Target: n/a
Current: $14.05
Upside: -
Merck & Co.
Apr 2, 2020
Maintains: Overweight
Price Target: n/a
Current: $129.22
Upside: -
Alkermes
Apr 2, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $24.54
Upside: -
Amneal Pharmaceuticals
Dec 14, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $6.05
Upside: -